Clearside Biomedical (CLSD) Reports In-Line Q3 EPS

Clearside Biomedical (NASDAQ: CLSD) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Sharon AI surges premarket; New Oriental gains, Medline slips